Michel “Mike” Morency, Ph.D.

Registered Patent Attorney, Boston, MA

Overview

Dr. Morency has over 20 years of legal practice with general corporate law firms, primarily in the life science industry. He holds a B.Sc. in Life Sciences, a Ph.D. in Medical Science – Neuroscience, and a J.D. in Common Law, providing him with a very strong educational background to represent life science companies. He has represented every segment of the life science industry, from early stage companies to large multi-national biopharmaceutical companies, as well as universities, and non-profit organizations.

Dr. Morency advises clients on the creation and development of cost-effective, strategic intellectual property (IP) portfolios. He also provides counseling to life science companies in patent interference, post-grant reviews, intellectual property enforcement, and litigation issues, as well as preparing patent invalidity, freedom to operate and non-infringement opinions. His legal experience encompasses numerous technologies such as neurobiology, stem cell and transgenic technologies, immunology and vaccine technologies, novel antibiotics, cancer therapeutics, tissue and organ regeneration, blood cells and blood products, drug delivery, drug discovery, gene therapy, genomics, proteomics, nanotechnologies, antioxidants, nutraceuticals and dietary supplement technologies, and medical devices.

In addition to the creation and management of IP portfolios and related counseling, Dr. Morency has extensive experience in the commercialization of IP, including the negotiation and drafting of transactional agreements for the transfer of intellectual property rights, such as IP licenses, material transfer agreements, strategic collaborations, mergers and acquisitions, as well as conducting due diligence related to various financings and transactions. This extensive experience representing large biopharmaceutical companies, investors, and underwriters provides Dr. Morency with a unique insight on creating IP portfolios that meet and exceeds the industry expectations, which enhances the technology’s valuation.

 

Education

University of Ottawa, J.D, cum laude

McMaster University, Ph.D in Medical Science - Neuroscience

Queen’s University, B.Sc., with honors, in Life Sciences

Admissions

Massachusetts

U.S. Patent and Trademark Office

Representative Matters
  • Advising life science companies on the creation and development of patent portfolios, collaborative research, licensing of technology, raising money through venture capital and other financial transactions, and enforcement of their intellectual property rights.
  • Providing patent invalidity, freedom to operate and non-infringement opinions Counseling life science companies in patent interference, post-grant reviews, intellectual property enforcement, and litigation issues.
  • Performing due diligence investigations for private and public financings and M&A transactions.
  • Negotiating and drafting various transactional agreements for the transfer of intellectual property rights.

Representative Transactions and Financings

Mergers & Acquisitions (M&A)

  • Represented a private, pre-clinical medical technology company in the sale of its royalty rights to a major institutional investor for $8 million USD.
  • Represented a privately-held specialty pharmaceutical company in an acquisition by a publicly-traded NASDAQ pharmaceutical company for $125 million USD plus milestones.
  • Represented a privately-held biomedical cancer therapeutic company in an acquisition/asset purchase by a publicly-traded NASDAQ biotech company for $55.3 million USD.
  • Represented a publicly-traded NASDAQ regenerative medicine company in the merger with two privately-held biotech companies to form a new publicly-traded NASDAQ regenerative medicine company.

Strategic Collaborations / Licensing

  • Represented a privately-held biomedical diagnostic company in a multi-year, worldwide Distribution Agreement with a Fortune 500 healthcare company.
  • Represented a publicly-traded NASDAQ genomics company in a Collaboration Agreement with a Fortune 500 pharmaceutical company worth over $1.5 billion USD.
  • Represented a privately-held biotech regenerative medicine company in an Exclusive Licensing Agreement with a Fortune 500 pharmaceutical company worth over $125 million USD, with $15 million USD upon signing.
  • Represented a subsidiary of a publicly-traded TYO pharmaceutical company in a Sponsored Research Agreement and an Exclusive License Agreement with an American university.

Initial Public Offerings (IPOs)

  • Represented a privately-held specialty pharmaceutical company in an IPO on NASDAQ for $70 million USD.
  • Represented the underwriters in the IPO of a privately-held molecular diagnostic company on NASDAQ for $82.5 million USD.
  • Represented the underwriters in the IPO of a privately-held biotechnology company on TSX for $42.4 million CDN, representing the largest Life Sciences IPO in Canada at the time.
Seminars / Publications

Seminars:

  • Moderator, presentation entitled, "Legal and Business Strategies for Early-Stage Med Tech” MedMates 2nd Annual Life Sciences Expo 2018, April 2018.  
  • Guest lecturer, Biotechnology Graduate Course entitled “The Importance of Intellectual Property in Biotechnology” Brown University, Fall 2016 and Fall 2017.  
  • Invited Speaker, presentation entitled, “MassChallenge Case Study:  Top IP Mistakes Made by Early Stage Technology Companies” MassChallenge Competition 2013, 2014, and 2015.  
  • Organizer and Moderator, presentation entitled, "Getting the Most from Your IP Budget:  Strategies for IP Portfolio Management and Litigation Avoidance" Foley’s Executive Briefing Series, Boston, Massachusetts, September 2009.  
  • Invited Speaker, presentation entitled, "Intellectual Property Strategies for Emerging Technology Companies" MIT Entrepreneurs Luncheon Series, Massachusetts Institute of Technology, Cambridge, MA, June 2006, 2007, and 2008.  
  • Invited Speaker, presentation entitled, "Intellectual Property Strategies for the Protection of Unique Food Products" Foley’s Quarterly Food Industry Web Conference Series, October 2007. 
  • Invited Speaker, presentation entitled, "From Idea to Effort to Operating Entity – An Entrepreneur's Guide" Babson Entrepreneurship Program, Babson College, Babson Park, MA, May 2007, 2008, and 2009.  

Publications:

  • "How to Respond to a Cease and Desist Letter."  NutraingredientUSA.com, J.F. Ewing, M. Flores, and M. Morency, February 2008.  
  •  “Patently wise: What, how and where to patent.” NutraingredientUSA.com, M. Morency and J.F. Ewing, October, 2007.
  • "Preparing for impending USPTO rule changes."  NutraIngredientUSA.com, J.F. Ewing and M. Morency, January 2007.  
  • “Preparing for a new round of impending US patent and trademark rule changes,” Mass High Tech, J.F. Ewing and M. Morency, September 2006.  
  • “Keeping trade secrets under wrap,” NutraIngredients-USA.com, J.F. Ewing, M. Morency, and S. Mollman Elliott, August 2006.  
  • “Preparing for a business transaction,” NutraIngredients-USA.com, J.F. Ewing and M. Morency, June 2006.   
  • “Preserving intellectual property before a patent is issued,” NutraIngredients-USA.com, J.F. Ewing and M. Morency, May 2006.  
  • “Nutraceuticals and functional foods require governance, present opportunity,” Mass High Tech, J.F. Ewing and M. Morency, October 3, 2005. 
  • “Knowledge generation, integration key in drug development strategies,” Mass High Tech, J.F. Ewing, J.M. Garvey, and M. Morency, July 6, 2004. 
  • “Rational Decisions:  Rational-drug-design firms are now under patent scrutiny. But this is a good thing.” Bio IT World, J.M. Garvey and M. Morency, June 17, 2004. 
  • “Computationally-Guided Rational Drug Design:  The Biotech Industry’s Rational Progression for New Drug Development,” Financier Worldwide / Biotechnology Sector Review, J.M. Garvey and M. Morency, June 2004, pp. 23 24.  
  • “Well-written IP strategy puts startups on roadmap for development,” Mass High Tech, J.M. Garvey and M. Morency, April 5, 2004.  
  • “Patent strategy can bring collaboration revenues,” Mass High TechM. Morency, J.F. Ewing, C. Pham, and J.M. Garvey, February 2, 2004.  
  • “Traps for the unwary,” Mass High TechM. Morency, J.F. Ewing, and J.M. Garvey, October 13, 2003.
  • “How to get licensees to help you monitor the market for infringers,” PatentWorld, J.M. Garvey, J.F. Ewing, and M. Morency, October 13, 2003. 

Scientific Publications:

  • Morency M., Quirion R., and Mishra R.K., Distribution of cholecystokinin receptors in the bovine brain: A quantitative autoradiographic study.  Neuroscience, 1994 Sep; 62(1): 307 - 316. 
  • Srivastava L.K., Morency M., and Mishra R.K., Ontogeny of dopamine D2 receptor mRNA in rat brain.  Eur. J. Pharmacol., 1992 Feb 13; 225(2): 143 -150. 
  • Morency M., Quirion R., Nair N.P., and Mishra R.K., Localization of cholecystokinin binding sites in canine brain using quantitative autoradiography.  Prog. Neuropsychopharmacol. Biol. Psychiatry,1991; 15(2): 291 -296. 
  • Srivastava L.K., Morency M., Bajwa S.B., and Mishra R.K., Effect of haloperidol on expression of dopamine Dreceptor mRNAs in rat brain.  J. Mol. Neurosci.,1990; 2(3): 155 -161. 
  • Morency M. and Mishra R.K., Cholecystokinin (CCK) receptors.  In: Peptide Hormone Receptors, (M. Kalimi and M.H. Hubbard, eds).  Walter de Gruyter, Berlin/New York, 1987 pp. 385-436.  
  • Morency M., Ross G.M., Hesketh D., and Mishra R.K., Effects of unilateral intracerebroventricular microinjections of cholecystokinin (CCK) on circling behavior of rats.  Peptides,1987 Nov-Dec; 8(6): 989-995.  
  • Morency M., Stewart R.J., and Beninger R.J., Circling behavior following unilateral microinjections of cocaine into the medial prefrontal cortex: dopaminergic or local anesthetic effect?  J. Neurosci.,1987 Mar; 7(3): 812-818. 
  • Beninger R.J., Cheng M., Hahn B.L., Hoffman D.C., Mazurski E.J., Morency M., Ramm P., and Stewart R.J., Effects of extinction, pimozide, SCH 23390, and metoclopramide on food-rewarded operant responding of rats. Psychopharmacology (Berl),1987; 92(3): 343-349. 
  • Morency M. and Beninger R.J., Dopaminergic substrates of cocaine-induced place conditioning.  Brain Res., 1986 Dec 3; 399(1): 33-41. 
  • Stewart R.J., Morency M., and Beninger R.J., Differential effects of intrafrontocortical microinjections of dopamine agonists and antagonists on circling behavior of rats.  Behav. Brain Res.,1985 Sep; 17(1): 67-72.
  • Morency M., Stewart R.J., and Beninger R.J., Effects of unilateral microinjections of sulpiride into the medial prefrontal cortex on circling behavior of rats.  Prog. Neuropsychopharmacol. Biol. Psychiatry,1985; 9(5-6): 735-738.  
Honors
  • Selected as a Massachusetts Super Lawyers 2004-2007.  
  • Over 20 scholarships, awards, and academic prizes, including a Licensing Executive Society (LES) Fellowship (1993-1994); a Medical Research Council (MRC) Studentship (1989-1991; ranked first overall in the national competition); and a Natural Sciences & Engineering Research Council Postgraduate Scholarship (1987-1989).  
Print PDF
Back to Top